Insider · CIK 0001867788
Sue-Jean Lin
Files at ARQT (Arcutis Biotherapeutics, Inc.), STVN (Stevanato Group S.p.A.). First filing Nov 25, 2025, latest Jun 17, 2026.
In brief
Sue-Jean Lin files SEC Form 4 as director at ARQT (Arcutis Biotherapeutics, Inc.), and also at STVN (Stevanato Group S.p.A.). Since Nov 25, 2025, Sue-Jean Lin has reported 0 open-market buys worth $0 and 2 open-market sells worth $899k, the latest filed on Jun 17, 2026.
A track record needs three past buys with six months of prices behind them; Sue-Jean Lin has 0, so none is measured yet.
The newest scored trade: sold $121k of ARQT on Jun 15, 2026, filed Jun 17, 2026, scored 18 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $899k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARQT: Arcutis Biotherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 18Weak | Arcutis Biotherapeutics, Inc. | $121k 4,946 shares | -15% | +93% from low-18% from high | |
| 47Moderate | Arcutis Biotherapeutics, Inc. | $778k 25,272 shares | -49% | +186% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | 4,946 0.00% of outstanding | $121k | Jun 15, 2026 | none |
| Nov 24, 2025 | ARQT Arcutis Biotherapeutics | 25,272 0.02% of outstanding | $778k | Nov 24, 2025 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | STVN Stevanato Group S.p.A. | AGrant or award Ordinary Shares | +4,975 | $0.00 | $0 | 6,975 | Jun 26, 2026 |
| Jun 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,946 | $24.38 | $121k | 27,567 | Jun 17, 2026 |
| Jun 5, 2026 | ARQT Arcutis Biotherapeutics, Inc. | AGrant or award Common Stock | +5,778 | $0.00 | $0 | 32,513 | Jun 9, 2026 |
| Jun 5, 2026 | ARQT Arcutis Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,667 | $0.00 | $0 | 16,667 | Jun 9, 2026 |
| Nov 24, 2025 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Common Stock | +18,052 | $8.63 | $156k | 44,787 | Nov 25, 2025 |
| Nov 24, 2025 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Common Stock | +7,220 | $7.51 | $54k | 52,007 | Nov 25, 2025 |
| Nov 24, 2025 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock | -25,272 | $30.78 | $778k | 26,735 | Nov 25, 2025 |
| Nov 24, 2025 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -18,052 | $0.00 | $0 | 9,000 | Nov 25, 2025 |
| Nov 24, 2025 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -7,220 | $0.00 | $0 | 5,000 | Nov 25, 2025 |
| Jun 12, 2025 | ARQT Arcutis Biotherapeutics, Inc. | AGrant or award Common Stock | +7,609 | $0.00 | $0 | 26,735 | Jun 16, 2025 |
| Jun 12, 2025 | ARQT Arcutis Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,568 | $0.00 | $0 | 20,568 | Jun 16, 2025 |
Questions about Sue-Jean Lin
Answered from the filings on this page, as of the latest one.
Is Sue-Jean Lin buying or selling?
In the last 12 months Sue-Jean Lin reported 0 open-market buys worth $0 and 2 open-market sells worth $899k on SEC Form 4; the latest was sold $121k of ARQT on Jun 15, 2026. Grants, option exercises and tax withholding are not counted.
How did Sue-Jean Lin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sue-Jean Lin has 0.
Where does Sue-Jean Lin file Form 4?
Sue-Jean Lin has filed Form 4 at ARQT (Arcutis Biotherapeutics, Inc.); STVN (Stevanato Group S.p.A.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.